What is gold’s rally signaling about the global economy? Barclays weighs in.
Director of Kestra Medical Technologies (NASDAQ:KMTS), Raymond W. Cohen, recently purchased 17,000 shares of common stock at $17.0 per share, totaling $289,000. The stock, currently trading at $17.86, has shown strong momentum with a 10.66% gain over the past week. According to InvestingPro, analyst price targets range from $20 to $30, suggesting potential upside.
The transaction, which occurred on March 7, 2025, increased Cohen’s direct ownership to 29,994 shares. These shares were purchased in connection with the company’s initial public offering reserved share program and were inadvertently omitted from prior filings. With the company’s next earnings report due on September 11, 2025, InvestingPro subscribers can access comprehensive insider trading analysis and 7 additional key insights about KMTS’s financial health.
Additionally, on September 4, 2025, Cohen acquired 10,909 restricted stock units, which will vest on September 4, 2026, subject to continued service. Following this transaction, Cohen directly owns 40,903 shares in the $873 million market cap company.
In other recent news, Kestra Medical Technologies reported strong fiscal fourth-quarter results, with total revenue reaching $17.2 million, marking a 71% increase compared to the previous year. This performance exceeded both Stifel and consensus estimates of $15.7 million, driven by a 43% growth in ASSURE prescription volume and enhancements in revenue cycle management. Despite mixed results with higher-than-expected operating expenses, Piper Sandler reiterated an Overweight rating for Kestra, setting a price target of $27.00, while Stifel maintained a Buy rating with a $28.00 target. In addition, Kestra held its 2025 annual general meeting, where approximately 95% of outstanding shares were represented, and shareholders approved director elections and a stock plan.
InspireMD appointed Raymond W. Cohen to its Board of Directors, bringing over 40 years of experience in medical technology. Cohen previously co-founded Axonics, Inc., which was acquired by Boston Scientific for $3.7 billion. Similarly, Biobeat Technologies named Cohen as Chairman of its Board of Directors, highlighting his extensive industry experience. Cohen’s leadership was instrumental in the sale of SoniVie, Ltd. to Boston Scientific for $600 million earlier this year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.